Compare AbbVie Inc (ABBV) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Tripadvisor Inc Common Stock — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Tripadvisor Inc Common Stock trades at $13.04 (market cap $1.66B). The key difference: AbbVie Inc is far larger — about 271× Tripadvisor Inc Common Stock's market cap, and AbbVie Inc pays a 2.72% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| ABBV | TRIP | |
|---|---|---|
Market Cap | $449.91B | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $19.14 |
52-Week Low | $184.85 | $9.24 |
Enterprise Value | $513.38B | $1.79B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
TRIP trades at $13.72, down 3.99% today, with a consensus price target of $13.87. The stock shows a bullish technical trend and recently announced the $700 million sale of TheFork to American Express. Despite mixed quarterly earnings, 2025 revenue grew to $1.89 billion with a net income margin of 0.99%. Analyst sentiment is mixed, with 60.72% holding and 23.21% recommending buy.
The outlook is cautiously optimistic. The sale of TheFork provides cash but removes a growth segment. Earnings volatility and competitive pressures in online travel pose risks. Upside depends on execution in core segments and macroeconomic stability. Current valuation metrics suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
